advertisement
Abstract #11307 Published in IGR 6-3
Efficacy and safety of the latanoprost/timolol maleate fixed combination vs concomitant brimonidine and latanoprost therapy
Stewart WC; Stewart JA; Day DG; Sharpe ED; Jenkins JNEye 2004; 18: 990-995
AIMS: To evaluate the efficacy and safety of latanoprost/timolol maleate fixed combination (LTFC) given once daily vs the concomitant therapy of brimonidine twice daily and latanoprost once daily in primary open-angle glaucoma or ocular hypertensive subjects. METHODS: A prospective, double-masked, active-controlled comparison in which qualified subjects had all glaucoma medicines discontinued for 1 month and then were randomized to either LTFC or brimonidine and latanoprost concomitant therapy for 6 weeks. They were then switched to the other treatment regimen. The intraocular pressure (IOP) was measured at 0800, 1200, and 1600 h at baseline and at the end of Periods 1 and Period 2. RESULTS: In 32 subjects, the diurnal curve of the untreated IOP of 26.0 ± 3.4 decreased to 17.8 ± 2.5 on LTFC and 17.2 ± 2.8 mmHg on brimonidine and latanoprost (P = 0.31). At 0800 and 1600 h, the IOPs were statistically similar between the groups (P > 0.05). At 1200 h the latanoprost and brimonidine treatment IOP was statistically lower (16.2 ± 3.2) than LTFC (18.0 ± 2.8 mmHg). However, the reduced IOP from untreated baseline was not statistically different at each time point and for the diurnal curve for each therapy (P < 0.05). Safety was similar between groups for both solicited and unsolicited side effects (P > 0.05). CONCLUSION: This study suggests that LTFC and concomitant therapy of brimonidine and latanoprost provide statistically similar diurnal IOP reduction from an untreated baseline.
Dr. W.C. Stewart, MD Pharmaceutical Research Network, LLC, 1639 Tatum Street, Charleston, SC, 29412, USA. prnc@bellsouth.net
Classification:
11.3.3 Apraclonidine, brimonidine (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
11.3.4 Betablocker (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
11.4 Prostaglandins (Part of: 11 Medical treatment)
